These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37239890)

  • 1. Old Drug, New Delivery Strategy: MMAE Repackaged.
    Lahnif H; Grus T; Salvanou EA; Deligianni E; Stellas D; Bouziotis P; Rösch F
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.
    Wang X; Sun R; Wang J; Li J; Walker E; Shirke A; Ramamurthy G; Shan L; Luo D; Carmon L; Basilion JP
    Theranostics; 2022; 12(5):2335-2350. PubMed ID: 35265213
    [No Abstract]   [Full Text] [Related]  

  • 4. A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer.
    Shirke AA; Walker E; Chavali S; Ramamurthy G; Zhang L; Panigrahi A; Basilion JP; Wang X
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
    Wang X; Shirke A; Walker E; Sun R; Ramamurthy G; Wang J; Shan L; Mangadlao J; Dong Z; Li J; Wang Z; Schluchter M; Luo D; Wang Y; Stauffer S; Brady-Kalnay S; Hoimes C; Lee Z; Basilion JP
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy.
    Liu X; Mohanty RP; Maier EY; Peng X; Wulfe S; Looney AP; Aung KL; Ghosh D
    J Control Release; 2020 Dec; 328():1-12. PubMed ID: 32798638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
    Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
    Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
    Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
    Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
    J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.